Clinical Trial Update: Adebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating neoadjuvant adebrelimab plus chemotherapy for resectable non-small cell lung cancer, with recruitment not yet starting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Adebrelimab (adebrelimab)
• Chemotherapy (chemotherapy)

Snippet

Sponsor: Zhangzhou Municipal Hospital | Conditions: Adebrelimab (SHR-1316), NSCLC | Phase 2 | Status: NOT_YET_RECRUITING